University of Wurzburg: Practice-Changing Study on Bone Marrow Cancer Therapy
January 17, 2024
January 17, 2024
WURZBURG, Germany, Jan. 17 (TNSres) -- The University of Wurzburg issued the following news release:
A team led by Wurzburg hematologist Hermann Einsele has defined a new first-line therapy for bone marrow cancer. The antibody "Daratumumab" is being used.
Daratumumab is a therapeutic monoclonal antibody that targets the protein "CD38", which is found in particular on tumour cells, especially myeloma cells. This means that daratumumab targets tumours . . .
A team led by Wurzburg hematologist Hermann Einsele has defined a new first-line therapy for bone marrow cancer. The antibody "Daratumumab" is being used.
Daratumumab is a therapeutic monoclonal antibody that targets the protein "CD38", which is found in particular on tumour cells, especially myeloma cells. This means that daratumumab targets tumours . . .